Skip to main content

Advertisement

SpringerLink
Log in

Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009–2010 mass vaccination campaign in France

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Moore N, Kreft-Jais C, Dhanani A (2007) Spontaneous reporting: France. In: Mann RD, Andrews E (eds) Pharmacovigilance, 2nd edn. John Wiley and Sons, Ltd, Chichester, pp 217–226

    Google Scholar 

  2. Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385–396

    Article  PubMed  Google Scholar 

  3. Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory authorities. Drug Saf 2:109–117

    Article  Google Scholar 

  4. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259

    Article  PubMed  CAS  Google Scholar 

  5. European Medicines Agency (EMA) (2009) CHMP Recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine, http://www.ema.europa.eu/pdfs/human/pandemicinfluenza/35938109en.pdf

  6. Asbury A, Cornblath D (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27:S21–S24

    Article  PubMed  Google Scholar 

  7. Polma CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al (2005) Diagnosis criteria for multiple sclerosis: 2005 revisions to the “Mc Donald Criteria”. Ann Neurol 58:840–846

    Article  Google Scholar 

  8. Black S, Eskola J, Siegrist C-A et al (2009) Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 374:2115–2122

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors acknowledge the following people for their valuable help during the vaccination campaign: P. Auriche (AFSSAPS), M. Clanet, L. Sailler, C. Paul (experts, CHU de Toulouse, France), M. Lapeyre-Mestre, F. Despas, A. Sommet, A. Pathak (Medical and Clinical Pharmacology, University of Toulouse) and Departments of PharmacoVigilance from pharmaceutical industries (GSK and Sanofi Pasteur).

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, Unité de Pharmacoépidémiologie, INSERM 1027, Université de Toulouse, Faculté de Médecine, Centre Hospitalier Universitaire, 37 allées Jules Guesde, 31000, Toulouse, France

    Céline Caillet, Genevieve Durrieu, Angeline Faucher & Jean-Louis Montastruc

  2. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), Paris, France

    Alexis Jacquet, Scheherazade Ouaret, Carmen Kreft-Jaïs & Anne Castot

  3. Association Française des Centres Régionaux de PharmacoVigilance, Paris, France

    Marie-Christine Perrault-Pochat

  4. Laboratoire de Pharmacologie Médicale et Clinique Faculté de Médecine, 37 allées Jules Guesde, 31000, Toulouse, France

    Genevieve Durrieu

Authors
  1. Céline Caillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Genevieve Durrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexis Jacquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angeline Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Scheherazade Ouaret
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marie-Christine Perrault-Pochat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carmen Kreft-Jaïs
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anne Castot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jean-Louis Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The French Network of Pharmacovigilance Centres

Corresponding author

Correspondence to Genevieve Durrieu.

Additional information

French Network of PharmacoVigilance Centres (CRPV): E. Autret-Leca, Tours; B. Baldin B, Nice; F. Bavoux, Paris St-Vincent de Paul; A. Bénard-Laribière, Bordeaux; M. Biour, Paris St-Antoine; MN. Beyens, Saint-Etienne; F. Colin, Rennes; A. Cocquerel, Caen; S. Crepin, Limoges; G. Décréau-Gaillon, Rouen; S. Dos Santos, Paris Henri Mondor; P. Eftekhari, Paris Fernand-Widal; S. Favrelière et MC. Perrault-Pochat, Poitiers; S. Gautier, Lille; V. Gras-Champel, Amiens; L. Javot, Nancy; MJ. Jean-Pastor, Marseille; C. Le Beller, Paris HEGP, B. Lebrun-Vignes, Paris Pitié-Salpétrière; A. Millaret, Lyon; A. Perrazi, Clermont-Ferrand; V. Pinzani, Montpellier; C. Riché, Brest; E. Schir, Grenoble; C. Sgro, Dijon; M. Tebacher-Alt, Strasbourg;T. Trenque, Reims; MB. Valnet-Rabier, Besançon; G. Veyrac, Nantes

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caillet, C., Durrieu, G., Jacquet, A. et al. Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009–2010 mass vaccination campaign in France. Eur J Clin Pharmacol 67, 649–651 (2011). https://doi.org/10.1007/s00228-010-0961-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-010-0961-8

Keywords

Search

Navigation